
News|Articles|August 15, 2026
DURAVYU Phase 3 DME trials COMO and CAPRI complete enrollment
Author(s)Kassi Filkins
EyePoint has finished enrolling both pivotal Phase 3 trials evaluating its sustained-release intravitreal insert against aflibercept in diabetic macular edema, setting up a topline readout in late 2027.
Advertisement
Advertisement
EyePoint, Inc. has completed enrollment in COMO (
Related to this article

The agreement brings J&J a next-generation bispecific antibody that outpaced faricimab on early anatomic measures in the phase 1b JADE trial, with Blackstone Life Sciences committing $750 million to fund phase 3 development.

Josef Huemer, MD, discusses retinal changes linked to atrial fibrillation and what they mean for eye care clinicians.

The first-in-human study of the GalNAc-conjugated siRNA joins a fast-moving Stargardt pipeline as the FDA weighs the first potential approval for the disease.

Katherine Talcott, MD, discusses phase 2 VERONA findings on the vorolanib intravitreal insert in previously treated DME.

VeonGen aligns with FDA on phase 3 design for VG801, a dual-AAV Stargardt gene therapy, after uncontrolled phase 1/2 BCVA gains.

Duravyu missed wet AMD noninferiority twice, DAYBREAK met its end points, and optogenetics won the Nobel as son-vec posted 4-year RP data in an AAO-driven October.
Advertisement
Advertisement


